Atiprimod is a synthetic small molecule that has been investigated primarily for its potential therapeutic applications, particularly in the treatment of certain hematological malignancies and inflammatory conditions. It functions as a selective inhibitor of specific signaling pathways, notably those involving the chemokine receptor CXCR4, which plays a crucial role in cell migration and proliferation. Atiprimod exhibits anti-inflammatory properties and has been studied for its ability to modulate immune responses. The compound is characterized by its relatively low molecular weight and specific structural features that facilitate its interaction with biological targets. In preclinical studies, Atiprimod has shown promise in reducing tumor growth and improving outcomes in models of disease. However, its clinical efficacy and safety profile continue to be evaluated through ongoing research. As with many investigational drugs, the full spectrum of its pharmacological effects, potential side effects, and therapeutic applications is still being explored in clinical trials.

Atiprimod

123018-47-3: Atiprimod is a synthetic small molecule that has been investigated primarily for its potential therapeutic applications, particularly in the treatment of certain hematological malignancies and inflammatory conditions. It functions as a selective inhibitor of specific signaling pathways, notably those involving the chemokine receptor CXCR4, which plays a crucial role in cell migration and proliferation. Atiprimod exhibits anti-inflammatory properties and has been studied for its ability to modulate immune responses. The compound is characterized by its relatively low molecular weight and specific structural features that facilitate its interaction with biological targets. In preclinical studies, Atiprimod has shown promise in reducing tumor growth and improving outcomes in models of disease. However, its clinical efficacy and safety profile continue to be evaluated through ongoing research. As with many investigational drugs, the full spectrum of its pharmacological effects, potential side effects, and therapeutic applications is still being explored in clinical trials.

2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl-

<p>Atiprimod: an oral azaspirane inhibiting STAT3, blocking IL-6/VEGF pathways, and promoting apoptosis by downregulating Bcl-2 and Mcl-1.</p>

CAS 123018-47-3

Atiprimod

2-Azaspiro[4.5]decane-2-propanamine, N,N-diethyl-8,8-dipropyl-

Ref: IN-DA000JZ9

Atiprimod (free base)

Ref: TM-T71176